Does REM sleep behavior disorder change in the progression of Parkinson's disease?


Journal

Sleep medicine
ISSN: 1878-5506
Titre abrégé: Sleep Med
Pays: Netherlands
ID NLM: 100898759

Informations de publication

Date de publication:
04 2020
Historique:
received: 23 09 2019
revised: 13 12 2019
accepted: 20 12 2019
pubmed: 12 2 2020
medline: 22 6 2021
entrez: 12 2 2020
Statut: ppublish

Résumé

Rapid eye movement (REM) Sleep Behavior Disorder (RBD) in Parkinson's disease (PD) may be associated with a malignant phenotype. Despite its prognostic value, little is known about the time course of RBD in PD. In this study, we aimed to ascertain whether or not RBD is a stable feature in PD. In this study, we prospectively evaluated clinical and neurophysiological features of RBD, including REM Sleep Without Atonia (RSWA), in PD patients with RBD at baseline and after three years then assessed whether the changes in measures of RSWA parallel the progression of PD. In sum, 22 (17M, mean age 64.0 ± 6.9 years) moderate-to-advanced PD patients (mean PD duration at baseline:7.6±4.8 years) with RBD, underwent a video-polysomnography (vPSG) recording and clinical and neuropsychological assessment at baseline and after three years. At follow-up, the self-assessed frequency of RBD symptoms increased in six patients, decreased in six and remained stable in 10, while RSWA measures significantly increased in all subjects. At follow-up, patients showed worse H&Y stage (p = 0.02), higher dopaminergic doses (p = 0.05) and they performed significantly worse in phonetic and semantic fluency tests (p = 0.02; p = 0.04). Changes in RSWA correlated significantly with the severity in levodopa-induced dyskinesia (r = 0.61,p = 0.05) and motor fluctuation (r = 0.54,p = 0.03) scores, and with the worsening of executive functions (r = 0.78,p = 0.001) and visuo-spatial perception (r = -0.57,p = 0.04). Despite the subjective improvement of RBD symptoms in one-fourth of PD patients, all RSWA measures increased significantly at follow-up, and their changes correlated with the clinical evolution of motor and non-motor symptoms. RBD is a long-lasting feature in PD and RSWA is a marker of the disease's progression.

Sections du résumé

OBJECTIVES/BACKGROUND
Rapid eye movement (REM) Sleep Behavior Disorder (RBD) in Parkinson's disease (PD) may be associated with a malignant phenotype. Despite its prognostic value, little is known about the time course of RBD in PD. In this study, we aimed to ascertain whether or not RBD is a stable feature in PD. In this study, we prospectively evaluated clinical and neurophysiological features of RBD, including REM Sleep Without Atonia (RSWA), in PD patients with RBD at baseline and after three years then assessed whether the changes in measures of RSWA parallel the progression of PD.
PATIENTS/METHODS
In sum, 22 (17M, mean age 64.0 ± 6.9 years) moderate-to-advanced PD patients (mean PD duration at baseline:7.6±4.8 years) with RBD, underwent a video-polysomnography (vPSG) recording and clinical and neuropsychological assessment at baseline and after three years.
RESULTS
At follow-up, the self-assessed frequency of RBD symptoms increased in six patients, decreased in six and remained stable in 10, while RSWA measures significantly increased in all subjects. At follow-up, patients showed worse H&Y stage (p = 0.02), higher dopaminergic doses (p = 0.05) and they performed significantly worse in phonetic and semantic fluency tests (p = 0.02; p = 0.04). Changes in RSWA correlated significantly with the severity in levodopa-induced dyskinesia (r = 0.61,p = 0.05) and motor fluctuation (r = 0.54,p = 0.03) scores, and with the worsening of executive functions (r = 0.78,p = 0.001) and visuo-spatial perception (r = -0.57,p = 0.04).
CONCLUSION
Despite the subjective improvement of RBD symptoms in one-fourth of PD patients, all RSWA measures increased significantly at follow-up, and their changes correlated with the clinical evolution of motor and non-motor symptoms. RBD is a long-lasting feature in PD and RSWA is a marker of the disease's progression.

Identifiants

pubmed: 32044557
pii: S1389-9457(19)31664-8
doi: 10.1016/j.sleep.2019.12.013
pii:
doi:

Substances chimiques

Levodopa 46627O600J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

190-198

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

M Figorilli (M)

EA 7280, UFR Medicine, University of Clermont Auvergne, Clermont-Ferrand, France; Sleep Disorder Center, Dept of Public Health & Clinical and Molecular Medicine. University of Cagliari, Italy.

A R Marques (AR)

EA 7280, UFR Medicine, University of Clermont Auvergne, Clermont-Ferrand, France; Neurology Department, CHU, Clermont-Ferrand, France.

T Vidal (T)

CMRR, CHU, Clermont-Ferrand, France.

L Delaby (L)

CMRR, CHU, Clermont-Ferrand, France.

M Meloni (M)

Sleep Disorder Center, Dept of Public Health & Clinical and Molecular Medicine. University of Cagliari, Italy.

B Pereira (B)

Biostatistics Unit (DRCI), CHU, Clermont-Ferrand, France.

C Lambert (C)

Biostatistics Unit (DRCI), CHU, Clermont-Ferrand, France.

M Puligheddu (M)

Sleep Disorder Center, Dept of Public Health & Clinical and Molecular Medicine. University of Cagliari, Italy.

F Durif (F)

EA 7280, UFR Medicine, University of Clermont Auvergne, Clermont-Ferrand, France; Neurology Department, CHU, Clermont-Ferrand, France.

M L Fantini (ML)

EA 7280, UFR Medicine, University of Clermont Auvergne, Clermont-Ferrand, France; Neurology Department, CHU, Clermont-Ferrand, France. Electronic address: mfantini@chu-clermontferrand.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH